share_log

Bristol-Myers Squibb | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Bristol-Myers Squibb | PRE 14A: Preliminary proxy statements relating to merger or acquisition

施貴寶 | PRE 14A：並購重組委托聲明
SEC announcement ·  03/19 05:26
牛牛AI助理已提取核心訊息
Bristol-Myers Squibb (BMS) announced the virtual 2024 Annual Meeting of Shareholders to be held on May 7, 2024. Shareholders of record as of March 14, 2024, are entitled to vote on several key proposals, including the election of 10 board directors, advisory vote on executive compensation, ratification of Deloitte & Touche LLP as the independent auditor, and an amendment to the Certificate of Incorporation for limited officer exculpation. Additionally, three shareholder proposals will be considered. The Board recommends votes for the election of directors, executive compensation, auditor ratification, and the charter amendment, but against all shareholder proposals. The meeting will also address the CEO transition, with Dr. Christopher Boerner succeeding Dr. Giovanni Caforio. BMS emphasizes the meeting's accessibility and the ability for shareholders to participate virtually.
Bristol-Myers Squibb (BMS) announced the virtual 2024 Annual Meeting of Shareholders to be held on May 7, 2024. Shareholders of record as of March 14, 2024, are entitled to vote on several key proposals, including the election of 10 board directors, advisory vote on executive compensation, ratification of Deloitte & Touche LLP as the independent auditor, and an amendment to the Certificate of Incorporation for limited officer exculpation. Additionally, three shareholder proposals will be considered. The Board recommends votes for the election of directors, executive compensation, auditor ratification, and the charter amendment, but against all shareholder proposals. The meeting will also address the CEO transition, with Dr. Christopher Boerner succeeding Dr. Giovanni Caforio. BMS emphasizes the meeting's accessibility and the ability for shareholders to participate virtually.
百時美施貴寶（BMS）宣佈將於2024年5月7日舉行虛擬的2024年年度股東大會。截至2024年3月14日，登記在冊的股東有權對幾項關鍵提案進行投票，包括選舉10名董事會董事，關於高管薪酬的諮詢投票，批准德勤會計師事務所作爲獨立核數師，以及對有限高管人員免職的公司註冊證書修正案。此外，還將考慮三項股東提案。董事會建議對董事選舉、高管薪酬、核數師批准和章程修正案進行投票，但反對所有股東提案。會議還將討論首席執行官的過渡問題，克里斯托弗·博爾納博士將接替喬瓦尼·卡福里奧博士。BMS強調會議的可訪問性以及股東虛擬參與的能力。
百時美施貴寶（BMS）宣佈將於2024年5月7日舉行虛擬的2024年年度股東大會。截至2024年3月14日，登記在冊的股東有權對幾項關鍵提案進行投票，包括選舉10名董事會董事，關於高管薪酬的諮詢投票，批准德勤會計師事務所作爲獨立核數師，以及對有限高管人員免職的公司註冊證書修正案。此外，還將考慮三項股東提案。董事會建議對董事選舉、高管薪酬、核數師批准和章程修正案進行投票，但反對所有股東提案。會議還將討論首席執行官的過渡問題，克里斯托弗·博爾納博士將接替喬瓦尼·卡福里奧博士。BMS強調會議的可訪問性以及股東虛擬參與的能力。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。